This playbook is a how-to guide in assessing potential CDMOs when initiating a switch to a new secondary or primary CDMO partner.
Whether you’re looking to source a secondary CDMO or looking for a primary CDMO, you’re not alone. The single contract development and manufacturing organization (CDMO) market has shifted dramatically over the past few years. Pressures include mergers and acquisitions, economic uncertainty, and supply chain disruptions. The resulting volatility has pharmaceutical companies experiencing cascading delays in cell and gene therapy (CGT) development.
This playbook explores how CGT developers can safeguard their operations by sourcing a CDMO with the technical capabilities and reliability that those programs require. To truly de-risk your program, you need an action plan to identify CDMO alternatives. Highlights include:
- A deep dive into why switching CDMOs is complex, particularly for cell and gene therapies.
- The four steps to identify whether a prospective CDMO is the right partner.
- A tips and strategies roadmap for efficiently onboarding a new CDMO, including best practices.
Offered Free by: BioPharma Dive’s studioID and Lonza
See All Resources from: BioPharma Dive’s studioID and Lonza
